Xtl Biopharmaceuticals (XTLB) Minority Interest (2012 - 2014)

Xtl Biopharmaceuticals (XTLB) has reported Minority Interest for 3 consecutive years, with $19000.0 the latest figure, recorded in Q4 2014.

• Quarterly Minority Interest fell 96.35% year-over-year to $19000.0 in Q4 2014, while the trailing twelve-month figure through Dec 2014 was $19000.0 (down 96.35% YoY) and the FY2014 annual result came in at $19000.0, down 96.35% from the prior year.
• Minority Interest slipped to $19000.0 in Q4 2014 per XTLB's latest filing, from $84000.0 in the prior quarter.
• Over the last five years, Minority Interest for XTLB reached as high as $2.1 million in Q4 2012 and fell as low as $19000.0 in Q4 2014.
• A 3-year average of $1.0 million and a median of $1.1 million in 2013 frame the typical range for Minority Interest.
• Annual changes were most pronounced in 2013 — Minority Interest fell 10.45% — and 2014, when it plunged 96.35%.
• Year by year, Minority Interest stood at $2.1 million in 2012, then plunged by 74.89% to $520000.0 in 2013, then tumbled by 96.35% to $19000.0 in 2014.
• According to Business Quant data, Minority Interest over the past three periods registered $19000.0, $84000.0, and $141000.0 for Q4 2014, Q3 2014, and Q2 2014 respectively.